Novartis Looks To Extend Top-Selling Cosentyx Into Juvenile Arthritis
Primary Endpoint Met In Phase III JUNIPERA Study
Top-line results from the Phase III JUNIPERA study of Novartis’s IL17A-targeting anti-inflammatory Cosentyx support its use in juvenile idiopathic arthritis, and the company intends to move quickly to enter the marketplace in pediatric patients with two subtypes of the condition.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Europe’s strengths in the biotech space include world-class science, but the continent needs to build on its strengths in order to deliver on the promise of a coming “golden age” of biotech, says a recent report.
Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.